Program
vorasidenib
Also written as “Vorasidenib”, “AG881” and “AG-881”.
Its studies are mostly in Astrocytoma · Glioma · Leukemia, Myeloid, Acute, led by 5 companies.
Drug pageVorasidenib: every studyMany companies study it; this page follows only the 12 they lead. All 25 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agios Pharmaceuticalsits history only | 50 open or running | phase 1since Jul 6, 2015 | Jul 6, 2015 | none ahead |
| Institut de Recherches Internationales Servier (I.R.I.S.)its history only | 42 open or running | phase 2since Dec 10, 2025 | Nov 14, 2025 | Nov 23, 2026phase 1 · NCT07250633 |
| Servierits history only | 11 open or running | phase 3since Dec 24, 2024 | Dec 24, 2024 | none ahead |
| Servier (Tianjin) Pharmaceutical | 11 open or running | no phasesince Apr 29, 2025 | Apr 29, 2025 | Apr 2028NCT06969352 |
| Servier Bio-Innovationits history only | 10 open or running | phase 1since Apr 19, 2023 | Apr 19, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Servier (Tianjin) Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2017Named vorasidenibINNProposed as its International Nonproprietary Name in WHO's List 117 · before, AG881, AG-881
- Apr 29, 2025First study: no phase study in GliomaFirst studyNCT06969352 · 62 enrolled · China
Ahead
- Apr 2028Primary completion: no phase study in GliomaNCT06969352
TargetBeta
“An orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, ”NCIt, by rule
“IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ranosidenibrule | HUTCHMED | phase 3 | 7 |
Studies
The one study Servier (Tianjin) Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06969352Glioma · China | – | Active, not recruiting | Apr 2028 | 62 |
How it is read
Names in the registry
- “Vorasidenib”, 5 entries
- “AG881”, 2 entries
- “AG-881”, 2 entries
- “Vorasidenib 20mg”, 1 entry
- “Vorasidenib 40 mg Oral Tablet”, 1 entry
Conditions, from the studies’ own filings
- Astrocytoma, 1 study
- Glioma, 1 study
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.